Cited by 197Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Prevalence of Alzheimer’s disease in very elderly people: A prospective neuropathological study

Open access
Polvikoski, T., Sulkava, R., Myllykangas, L., Notkola, I.-L., Niinistö, L., Verkkoniemi, A., Kainulainen, K., Kontula, K. +3 more·2001·Neurology

Abstract

BACKGROUND: No previous autopsy-controlled, prospective, and population-based studies are available on the prevalence of AD in very elderly people. OBJECTIVE: To study the point prevalence of neuropathologically defined AD in a population of people at least 85 years of age, stratified according to their APOE genotype. METHODS: A population-based sample of 532 (of a total population of 601) elderly Finnish individuals, aged 85 years or more, were clinically tested for dementia in 1991 (with follow-up studies of the survivors in 1994, 1996, and 1999) and genotyped for APOE. An autopsy involving neuropathologic diagnosis of AD according to modified consensus criteria was performed in 118 of 198 deceased subjects who had been demented on April 1, 1991, and in 62 of 201 nondemented individuals. RESULTS: The prevalence of neuropathologically defined AD was 33%, whereas the prevalence of clinically diagnosed AD was 16%. There was a highly significant (p < 0.001) association between the APOE epsilon4 allele and AD: Sixty-three percent of APOE epsilon4 carriers and 20% of noncarriers had neuropathologic AD. The respective figures in subjects aged 90 years or more were 71 and 22%. CONCLUSIONS: The prevalence of neuropathologically defined AD is higher than that reported in most previous studies based on clinical diagnosis. The discrepancy between the neuropathologic and clinical diagnoses of AD in very elderly subjects may affect the results of population-based studies. The APOE genotype has a strong effect on the prevalence of neuropathologically defined AD, even after 90 years of age.

Integrity signals

Registry

Crossref · 10.1212/wnl.56.12.1690

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A sizable percentage of non-demented elderly have plaques.

    “Decades of clinical-pathological correlative studies, now corroborated by a decade of neuroimaging studies, also demonstrate a sizable percentage of the non-demented elderly have plaques [40, 51, 54, 55, 58–68].”

    From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [63]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Polvikoski, T., Sulkava, R., Myllykangas, L., Notkola, I.-L., Niinistö, L., Verkkoniemi, A., Kainulainen, K., Kontula, K., Pérez–Tur, J., Hardy, J., & Haltia, M.
Affiliations
  • University of Helsinki (FI)
  • From the Departments of Pathology (Drs. Polvikoski, Myllykangas, Verkkoniemi, and Haltia), Neurology (Dr. Verkkoniemi), and Medicine (Drs. Kainulainen and Kontula), University of Helsinki and Helsinki University Central Hospital, Finland; Faculty of Social Sciences (Dr. Notkola), University of Helsinki; Department of Public Health and General Practice (Dr. Sulkava), Division of Geriatrics, University of Kuopio and Kuopio University Hospital, Finland; Katriina Geriatric Hospital (Dr. Niinistö),...
Venue
Neurology
Published
2001-06-26
Volume
56
Issue
12
Pages
1690-1696
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2060355242
Cited by
197
References
41
Citations by year
2026: 4 · 2025: 6 · 2024: 5 · 2023: 6 · 2022: 4 · 2021: 5 · 2020: 25 · 2019: 6 · 2018: 4 · 2017: 4 · 2016: 7 · 2015: 2 · 2014: 6 · 2013: 10 · 2012: 5
FWCI
7.90
Type
journal article
Language
en
Open access
Locations
  • Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • Newcastle University ePrints (Newcastle Univesity)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, oldest old, prevalence, APOE ε4, APOE genotype, dementia, autopsy
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Finland, Genotype, Humans, Male, Prospective Studies, Prevalence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review